OBJECTIVE: Thrombotic microangiopathy (TMA) is a characteristic feature of HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome, but low-grade hemolysis and thrombocytopenia may also occur with preeclampsia. We sought to evaluate the prevalence and impact of low-grade, smoldering TMA in preeclampsia. STUDY DESIGN: Retrospective cohort study (Oct '13 -Apr '18) at a single institution among all subjects 23 weeks gestation who delivered with a diagnosis of preeclampsia. Subjects were identified by ICD-9 and ICD-10 codes, followed by manual chart review to confirm diagnosis. Women were stratified into two groups by presence or absence of smoldering TMA, defined as abnormal lactate dehydrogenase (LDH) level (>250 U/L) in combination with abnormal platelet count (<150 k/ml) before delivery. Subjects with only one feature (e.g., abnormal platelet count but normal LDH) were in the non-TMA group. Those meeting criteria for HELLP syndrome were excluded. Primary endpoints were adverse maternal and neonatal outcomes. Laboratory data were abstracted as peak values [aspartate transaminase (AST, U/L); creatinine (mg/dl); LDH (U/L)] or nadir values [hemoglobin (g/dl); platelet count (k/ml)] before delivery. Data were analyzed by t-test, Chi-squared test and logistic regression, with a¼0.05.
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RESULTS: Among 10,833 deliveries, 766 (7.1%) had preeclampsia. Of these, 96 (12.5%) had smoldering TMA, and subject characteristics are shown in Table 1 . After multivariable adjustment, TMA was increased in association with nulliparity (aOR 2.06, p¼0.006) and multiple gestation (aOR 2.26, p¼0.03), and decreased with chronic hypertension (aOR 0.33, p¼0.004). Pregnancy outcomes with smoldering TMA are shown in Table 2 . Adverse maternal outcomes (composite) were increased with TMA (30.2% vs. 20.6%, p¼0.033), but the association was attenuated after multivariable adjustment (aOR 1.35, p¼0.24) . Adverse neonatal outcomes were also increased with TMA, and the association between preterm birth <34 weeks and TMA remained significant after multivariable adjustment (aOR 2.16, p¼0.009). CONCLUSION: We find that smoldering TMA is common in preeclampsia and is associated with adverse pregnancy outcomes, most notably preterm birth <34 weeks. Caution is warranted when both low-grade hemolysis and thrombocytopenia are detected in the setting of preeclampsia.
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